Key result
A nanoparticle-based LDI-MS immunoassay detected EV71 in clinical serum samples with >95% agreement compared to RT-qPCR results.
Why the study?
Viral epidemics cause serious public health emergencies, creating a high demand for reliable, multiplex screening assays to simultaneously detect and rapidly screen high-risk pathogens.
Effect estimate: >95% agreement
A novel nanoparticle-based LDI-MS immunoassay provides a simple, reliable, and high-throughput platform for the simultaneous detection of multiple viral infections.
Supports LDI-MS immunoassay development for EV71; leaves open clinical adoption pending larger validation.
Many serious public health emergencies around the globe are caused by viral epidemics. Thus, developing a reliable method for viral screening is in high demand. Multiplex assays for simultaneous detection and fast screening of high-risk pathogens are especially needed. This study employs metal nanoparticles to generate specific mass spectral signals for different RNA viruses, which enables simultaneous detection of whole viruses by laser desorption/ionization mass spectrometry (LDI-MS). We developed a nanoparticle-based sandwich immunosorbent assay as a sensing platform for the detection of viruses and viral nonstructural protein by LDI-MS. Cellulose acetate membrane (CAM) serves as the substrate for the fabrication of the sandwich immunosorbent assay with the advantages of clean mass spectra and high enrichment of analytes. Antibody-modified metal nanoparticles (Ab–MNPs; M = Au or Ag) act as metallic biocodes for the LDI-MS detection. The signal amplification readout for the virus is through the pulsed laser-induced formation of metal cluster ions ([M n ] +; n = 1–3) from the Ab–MNPs which specifically bind on the CAM. Our sensing system is effective for the detection of intact viruses [Enterovirus 71 (EV71) and Japanese encephalitis virus (JEV)], nonstructural protein 1 (NS1) of Zika virus (ZIKV), EV71-spiked human serum samples, and the simultaneous detection of EV71 and ZIKV. Our probe efficiently detects EV71 in real clinical serum samples with >95% agreement with RT-qPCR results. This high-throughput LDI-MS viral detection system is simple, reliable, and high-throughput. We believe this platform has the potential to be employed for the routine screening of patients with viral infections.
No takes yet. Share an insight, caveat, or question.
Chu et al. (2019) studied Viral infections (EV71, JEV, ZIKV). Nanoparticle-based LDI-MS immunoassay vs. RT-qPCR was evaluated on Agreement with RT-qPCR results for EV71 detection in clinical serum samples (>95% agreement). A nanoparticle-based LDI-MS immunoassay detected EV71 in clinical serum samples with >95% agreement compared to RT-qPCR results.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: